Insider · CIK 0001412071
Shawn Singh
Files at VTGN (Vistagen Therapeutics, Inc.). First filing -, latest -.
In brief
Shawn Singh files SEC Form 4 as CEO, president and director at VTGN (Vistagen Therapeutics, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Shawn Singh has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 5 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 30, 2026 | VTGN Vistagen Therapeutics, Inc. | AGrant or award Common Stock | +36,818 | $0.19 | $7,073 | 54,846 | Jul 2, 2026 |
| Apr 7, 2026 | VTGN Vistagen Therapeutics, Inc. | AGrant or award Incentive Stock Option (right to buy)derivative | +3,732 | $0.00 | $0 | 3,732 | Apr 9, 2026 |
| Apr 7, 2026 | VTGN Vistagen Therapeutics, Inc. | AGrant or award Non-Qualified Stock Option (right to buy)derivative | +71,268 | $0.00 | $0 | 71,268 | Apr 9, 2026 |
| Jun 30, 2025 | VTGN Vistagen Therapeutics, Inc. | AGrant or award Common Stock | +7,541 | $1.70 | $13k | 18,028 | Jul 1, 2025 |
| Jun 23, 2025 | VTGN Vistagen Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +300,000 | $0.00 | $0 | 300,000 | Jun 25, 2025 |
Questions about Shawn Singh
Answered from the filings on this page, as of the latest one.
Is Shawn Singh buying or selling?
Shawn Singh has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Shawn Singh's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Shawn Singh has 0.
Where does Shawn Singh file Form 4?
Shawn Singh has filed Form 4 at VTGN (Vistagen Therapeutics, Inc.) as President and CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.